AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studySystematic reviewPeer-reviewed
Investigating Gut Microbiota in Multiple Sclerosis (MS)
A systematic review examined the relationship between gut dysbiosis and immune responses in MS, finding links to impaired regulation and increased inflammation from pro-inflammatory T-cell responses and functional changes related to oxidative stress and metabolism.
- Tags
- #Other
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
These findings highlight the potential role of gut microbiota in MS by detailing how dysbiosis may disrupt immune regulation, contributing to the disease, paving the way for potential future interventions.
What this does not prove
However, current interventions are investigational and not yet established therapies for MS, and many findings depend on hypotheses needing further validation.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not applicable
- Controlled
- Not applicable
- Primary endpoint met
- Not applicable
- Relevant MS type
- Not reported
- Publication date
- 2026-10-08
- Evidence reviewed
- Abstract only
- Regulatory approval
- No
- Research areas
- Other
Original sources
- Primary evidenceToward regionally equitable precision medicine: microbiota‑associated mechanisms and emerging personalized strategies in multiple sclerosis. ↗DOI: 10.1186/s12967-026-08830-7
Supporting passages (13)
study phasecurrent microbiota-targeted interventions remain investigational rather than established disease-modifying therapies for MS.
study designThis review synthesizes global evidence alongside emerging data from underrepresented regions, including Egypt, Iran, and India, to delineate molecular pathways linking MS-associated dysbiosis to immune dysregulation.
subjectsIncreasing evidence implicates the gut microbiota as a key modulator of host immune homeostasis; however, current understanding is largely derived from Western cohorts and remains fragmented at the mechanistic level.
randomizedcurrent microbiota-targeted interventions remain investigational rather than established disease-modifying therapies for MS.
controlledcurrent microbiota-targeted interventions remain investigational rather than established disease-modifying therapies for MS.
peer reviewedThis review synthesizes global evidence alongside emerging data from underrepresented regions, including Egypt, Iran, and India, to delineate molecular pathways linking MS-associated dysbiosis to immune dysregulation.
primary endpoint metSeveral regional signatures reported here derive from a single pilot-scale cohort and should be regarded as hypothesis-generating pending independent validation, and current microbiota-targeted interventions remain investigational rather than established disease-modifying therapies for MS.
regulatory approvalcurrent microbiota-targeted interventions remain investigational rather than established disease-modifying therapies for MS.
research categoriesThis review synthesizes global evidence alongside emerging data from underrepresented regions, including Egypt, Iran, and India, to delineate molecular pathways linking MS-associated dysbiosis to immune dysregulation.
publication datePublication date: 2026-10-08
interventionWe critically examine microbiota-derived signals, including short-chain fatty acids, lipopolysaccharide, and polysaccharide A, that modulate dendritic cell programming, regulatory T-cell differentiation, and neuroinflammatory cascades.
findingsAcross studies, dysbiosis is consistently associated with impaired short-chain fatty acid-mediated immunoregulation, skewing toward proinflammatory Th1/Th17 responses, and disruption of intestinal and blood-brain barrier integrity, with region-dependent functional signatures involving oxidative stress and neurotransmitter and tryptophan metabolism.
limitationsSeveral regional signatures reported here derive from a single pilot-scale cohort and should be regarded as hypothesis-generating pending independent validation, and current microbiota-targeted interventions remain investigational rather than established disease-modifying therapies for MS.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.